Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS breakthrough? trial tests if older patients can ditch heavy drugs

NCT ID NCT07189325

Recruiting now Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease activity and disability worsening just as well as staying on the stronger therapy. The trial will involve 250 participants and aims to reduce treatment burden while maintaining control of the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis Recurrence relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-CD20 THERAPY RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Neurology Department, Hospital Gui de Chauliac

    RECRUITING

    Montpellier, 34295, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact